Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà Ferrer, Meritxell
  • Grau Exposito, Judith
  • Buzon, Maria Jose
HIV infections; Restriction factors, Infecciones por VIH; Factores de restricción, Infeccions pel VIH; Factors de restricció, Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption

  • Perea Pérez, David
  • Martin-Gayo, Enrique
  • Zamora Carrillo, Jorge Ivan
  • Sánchez Gaona, Nerea
  • Curran, Adrian
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
NK cell; Bispecific antibody therapy; HIV, Cèl·lules NK; Teràpia d'anticossos biespecífics; VIH, Células NK; Terapia d'anticuerpos biespecíficos; VIH:es, HIV infection remains incurable as the virus persists within a latent reservoir of CD4+T cells. Novel approaches to enhance immune responses against HIV are essential for effective control and potential cure of the infection. In this study, we designed a novel tetravalent bispecific antibody (Bi-Ab32/16) to simultaneously target the gp120 viral protein on infected cells, and the CD16a receptor on NK cells. In vitro, Bi-Ab32/16 triggered a potent, specific, and polyfunctional NK-dependent response against HIV-infected cells. Moreover, addition of the Bi-Ab32/16 significantly reduced the latent HIV reservoir after viral reactivation and mediated the clearance of cells harboring intact proviruses in samples from people with HIV (PWH). However, the in vivo preclinical evaluation of Bi-Ab32/16 in humanized mice expressing IL-15 (NSG-Hu-IL-15) revealed a significant decline of NK cells associated with poor virological control after ART interruption. Our study underscores the need to carefully evaluating strategies for sustained NK cell stimulation during ART withdrawal., This study was supported by the Spanish Secretariat of Science and Innovation, FEDER funds (RTI2018-101082-B-I00, PID2021-123321OB-I00, PDC2022.133836-100), two Gilead fellowships (GLD21/00049, GLD22/00152) as well as partially funded by the PI20/00160 grant from the Spanish Health Institute Carlos III, co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, the CNS2022-135549 grant, funded by MCIN/AEI/10.13039/501100011033 and by the European Union «Next Generation EU»/PRTR. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005). N.S-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (PRE2019-087393). We would like to thank Dr. Julia G. Prado from IrsiCaixa Institute for AIDS Research for generating the viral stock R5-BaL and Jorge Díaz from the Comparative Medicine and Bioimage Centre of Catalonia (CMCIB) for its excellent technical assistance with in vivo animal studies. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence

  • Astorga Gamaza, Antonio
  • Buzón Gómez, María José
Marcadors cel·lulars; Virus de la immunodeficiència humana; Persistència viral, Marcadores celulares; Virus de la inmunodeficiencia humana; Persistencia viral, Cell markers; Human immunodeficiency virus; Viral persistence, Purpose of review To discuss the role of CD4+ T cells with active Human immunodeficiency virus (HIV), meaning infected cells with transcriptional and/or translational viral activity during antiretroviral therapy (ART), focusing on new technologies for its detection, potential cell markers for its characterization, and evidences on the contribution of the active HIV reservoir to long-term viral persistence. Recent findings HIV-infected cells expressing viral ribonucleic acid are systematically detected in subjects on long-term ART. In recent years, powerful new tools have provided significant insights into the nature, quantification, and identification of cells with active HIV, including the identification of new cell markers, and the presence of viral activity in specific cell populations located in different cellular and anatomical compartments. Moreover, studies on viral sequence integrity have identified cell clones with intact viral genomes and active viral transcription that could potentially persist for years. Together, new investigations support the notion that the active reservoir could represent a relevant fraction of long-term infected cells, and therefore, the study of its cell sources and mechanisms of maintenance could represent a significant advance in our understanding of viral persistence and the development of new curative strategies. Summary The presence of HIV-infected cells with viral expression during ART has been traditionally overlooked for years. Based on recent investigations, this active viral reservoir could play an important role in HIV persistence., This work was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), and the Fundació La Marató TV3 (grant 201805-10FMTV3). M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A.-G. is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016-076382). The funders had no role in the decision to publish or the preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency

  • Gallego-Cortés, Ana
  • Sánchez Gaona, PhD, Nerea
  • Ruiz Isant, Oriol
  • Pumarola, Felix
  • Ortiz Laredo, Nuria
  • Llano Espinosa, Ines
  • Mañalich-Barrachina, Laura
  • Mancebo Pérez, Cristina
  • Benítez Martínez, Aleix
  • Landolfi, Stefania
  • Castellvi, Josep
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV; Tissue models; Cellular reservoirs, VIH; Modelos de tejido; Reservorios celulares, VIH; Models de teixit; Reservoris cel·lulars, HIV persists in diverse tissues, with distinct cellular reservoirs presenting a major barrier to a cure and requiring targeted therapeutic strategies to address this heterogeneity. Here, we develop tissue models of HIV latency using human tonsillar, intestinal and cervicovaginal tissues. These models reveal differential HIV infection across CD4+ T-cell subpopulations, with ART partially restoring CD4+ T cells and reducing intact HIV DNA. T follicular helper cells (TFH CD69+ CCR7-) are the primary inducible reservoir in tonsils, while tissue-resident memory cells (TRM CD69+ CD49a+) dominate in the intestine. Identification of markers for inducible reservoirs shows that CD69, CD45RO, and PD-1 are shared across tissues, while CXCR5 in tonsils and CD49a in the intestine act as tissue-specific markers. Furthermore, using different latency reversal agents (LRAs) demonstrates that Histone Deacetylase Inhibitors (HDACis) fail to induce HIV in any tissue, the SMAC mimetic AZD5582 is effective only in a resident-memory CD4+ T-cell subpopulation in the intestine, and IL-15 exhibits the broadest reactivation potential across tissues and CD4+ T-cell subsets. These models provide insights into the inducible reservoir's composition in different tissues and inform strategies for its elimination., This study was funded by “la Caixa” Foundation (ID 100010434) under the project code LCF/PR/HR20/00218. This study also received funding from the Agencia Estatal de Investigación project PID2021-123321OB-I00 and PID2024-155881OB-100 supported by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD21-00049, GLD22/00152 and GLD24/00014. MJB is supported by the Miguel Servet programme of the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005), and AGC is a recipient of a PhD fellowship from “la Caixa” Foundation (LCF/BQ/DI20/11780014). The funders had no role in the design of the study, data collection or analysis, decision to publish, or manuscript preparation. We acknowledge María Lázaro and Ruth Peña (JGP research group) for their technical assistance in the production of the HIVBAL viral stock.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

  • Kladnik, Jerneja
  • Dolinar, Ana
  • Kljun, Jakob
  • Grau Exposito, Judit
  • Genesca Ferrer, Meritxell
  • Novinec, Marko
  • Buzón Gómez, María José
  • Turel, Iztok
  • Perea Pérez, David
SARS-CoV-2; Inhibition; Zinc, SARS-CoV-2; Inhibició; Zinc, SARS-CoV-2; Inhibición; Zinc, Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc pyrithione revealed potent in vitro inhibition of cathepsin L (IC50=1.88 ± 0.49 µM) and PLPro (IC50=0.50 ± 0.07 µM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc complexes 1b–h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2., The authors acknowledge the financial support from the Slovenian Research Agency ARRS [Research Core Funding No. P1-0175 together with an increase in research programme funding related to the COVID-19 pandemic], and the grant from the Health Department of the Government of Catalonia [DGRIS 1_5] and the Fundació La Marató TV3 [Grants 202104FMTV3 and 202112FMTV3] to M.G. and MJ.B. MJ.B is supported by the Miguel Servet Program funded by the Spanish Health Institute Carlos III [CP17/00179].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response

  • Grau Exposito, Judit
  • Navarro Mercadé, Jordi
  • Curran Fàbregas, Adria
  • Planas Ribas, Bibiana
  • Suanzes Diez, Paula
  • Falcó Ferrer, Vicenç
  • Genesca Ferrer, Meritxell
  • Buzón Gómez, María José
  • Astorga Gamaza, Antonio
  • Burgos Cibrian, Joaquin
HIV; Infectious disease; Reservoir, VIH; Malalties infeccioses; Reservori, VIH; Enfermedades infecciosas; Reservorio, Human immunodeficiency virus (HIV) establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy (ART), but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32., This study was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI17/01470), GeSIDA and the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-10FMTV3) and the Gilead fellowships GLD19/00084 and GLD18/00008. M.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016–076382). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV

  • Sanchez-Cerrillo, Ildefonso
  • Martin-Cofreces, Noa B
  • Martínez-Fleta, Pedro
  • de la Fuente, Hortensia
  • Buzón Gómez, María José
  • Calvet-Mirabent, Marta
  • Tsukalov, Ilya
HIV; Immunotherapy; Metabolism, VIH; Inmunoterapia; Metabolismo, VIH; Immunoteràpia; Metabolisme, Background Dysfunction of CD8+ T cells in people living with HIV-1 (PLWH) receiving anti-retroviral therapy (ART) has restricted the efficacy of dendritic cell (DC)-based immunotherapies against HIV-1. Heterogeneous immune exhaustion and metabolic states of CD8+ T cells might differentially associate with dysfunction. However, specific parameters associated to functional restoration of CD8+ T cells after DC treatment have not been investigated. Methods We studied association of restoration of functional HIV-1-specific CD8+ T cell responses after stimulation with Gag-adjuvant-primed DC with ART duration, exhaustion, metabolic and memory cell subsets profiles. Findings HIV-1-specific CD8+ T cell responses from a larger proportion of PLWH on long-term ART (more than 10 years; LT-ARTp) improved polyfunctionality and capacity to eliminate autologous p24+ infected CD4+ T cells in vitro. In contrast, functional improvement of CD8+ T cells from PLWH on short-term ART (less than a decade; ST-ARTp) after DC treatment was limited. This was associated with lower frequencies of central memory CD8+ T cells, increased co-expression of PD1 and TIGIT and reduced mitochondrial respiration and glycolysis induction upon TCR activation. In contrast, CD8+ T cells from LT-ARTp showed increased frequencies of TIM3+ PD1− cells and preserved induction of glycolysis. Treatment of dysfunctional CD8+ T cells from ST-ARTp with combined anti-PD1 and anti-TIGIT antibodies plus a glycolysis promoting drug restored their ability to eliminate infected CD4+ T cells. Interpretation Together, our study identifies specific immunometabolic parameters for different PLWH subgroups potentially useful for future personalized DC-based HIV-1 vaccines., EMG was supported by the NIH R21 program (R21AI140930), the Ramón y Cajal Program (RYC2018-024374-I), the MINECO/FEDER RETOS program (RTI2018-097485-A-I00), by Comunidad de Madrid Talento Program (2017-T1/BMD-5396) and by Gilead becas de investigación (GLD19/00168). EMG and IDS are supported by Centro de Investigación Biomédica en Red (CIBERINF) de Enfermedades Infecciosas (CB21/13/00107). MCM was supported by NIH R21 program (R21AI140930), “La Caixa Banking Foundation (H20-00218) and Gilead becas de investigación (GLD19/00168). MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179), the MINECO/FEDER RETOS program (RTI2018-101082-B-100), and Fundació La Marató TV3 (201805-10FMTV3). EMG and MJB are both funded by “La Caixa Banking Foundation (H20-00218) and by REDINCOV grant from Fundació La Marató TV3. FSM was supported by SAF2017-82886-R and PDI-2020-120412RB-I00 grants from the Ministerio de Ciencia e Innovación, and HR17-00016 grant from “La Caixa Banking Foundation. HF was funded by PI21/01583 grant from Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III. MJC was supported by PID2019-104406RB-I00 from Ministerio de Ciencia e Innovación. ISC was funded by the CM21/00157 Rio-Hortega grant. IT was supported by grant for the promotion of research studies master-UAM 2021.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1

  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Cantero, Jon|||0000-0003-4844-6143
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Benet, Susana|||0000-0002-2219-8826
  • Pino, M.
  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Hernández Gallego, Alba|||0000-0002-4595-468X
  • Castellvi, Josep|||0000-0001-5745-9996
  • Tapia, G.
  • Arnau-Saz, V.
  • Garrido, Joseba M.
  • Tarrats, Antoni|||0000-0002-1276-8522
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martinez-Picado, J.
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
Antigen presenting cells from the cervical mucosa are thought to amplify incoming HIV-1 and spread infection systemically without being productively infected. Yet, the molecular mechanism at the cervical mucosa underlying this viral transmission pathway remains unknown. Here we identified a subset of HLA-DR+ CD14+ CD11c+ cervical DCs at the lamina propria of the ectocervix and the endocervix that expressed the type-I interferon inducible lectin Siglec-1 (CD169), which promoted viral uptake. In the cervical biopsy of a viremic HIV-1+ patient, Siglec-1+ cells harbored HIV-1-containing compartments, demonstrating that in vivo, these cells trap viruses. Ex vivo, a type-I interferon antiviral environment enhanced viral capture and trans-infection via Siglec-1. Nonetheless, HIV-1 transfer via cervical DCs was effectively prevented with antibodies against Siglec-1. Our findings contribute to decipher how cervical DCs may boost HIV-1 replication and promote systemic viral spread from the cervical mucosa, and highlight the importance of including inhibitors against Siglec-1 in microbicidal strategies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Luque-Ballesteros, Laura|||0000-0001-9515-5889
  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Navarro, Jordi|||0000-0002-7187-0367
  • Gallego-Rodriguez, Jenny
  • Martín Castillo, Mario|||0000-0001-6435-0374
  • Curran, Adrian|||0000-0002-1263-0814
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Ribera, Esteban|||0000-0002-3752-8808
  • Raventós, Berta|||0000-0002-4668-2970
  • Willekens, Rein|||0000-0001-7791-3682
  • Torrella Domingo, Adriana|||0000-0003-1848-5096
  • Planas, Bibiana|||0000-0002-1490-7127
  • Badía, Rosa|||0000-0002-8222-5697
  • García, Felipe|||0000-0001-7658-5832
  • Castellvi, Josep|||0000-0001-5745-9996
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

  • Cantero, Jon|||0000-0003-4844-6143
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Serra-Peinado, Carla|||0000-0003-1413-3990
  • Rosero, Daniela A.|||0000-0002-3212-2710
  • Luque-Ballesteros, Laura|||0000-0001-9515-5889
  • Astorga-Gamaza, Antonio|||0000-0002-1276-5276
  • Castellvi, Josep|||0000-0001-5745-9996
  • Sanhueza, Tamara
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Lloveras, Belen|||0000-0001-8659-5241
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Prado, Julia G.|||0000-0002-5439-4645
  • Sole Sedeño, Josep Maria|||0000-0002-0789-6896
  • Tarrats, Antoni|||0000-0002-1276-8522
  • Lecumberri, Carla|||0000-0001-6509-5256
  • Mañalich Barrachina, Laura|||0000-0002-4624-4671
  • Centeno Mediavilla, Maria Cristina|||0000-0002-7181-3063
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
HIV viral reservoirs are established very early during infection. Resident memory T cells (T) are present in tissues such as the lower female genital tract, but the contribution of this subset of cells to the pathogenesis and persistence of HIV remains unclear. Here, we show that cervical CD4T display a unique repertoire of clusters of differentiation, with enrichment of several molecules associated with HIV infection susceptibility, longevity and self-renewing capacities. These protein profiles are enriched in a fraction of CD4T expressing CD32. Cervical explant models show that CD4T preferentially support HIV infection and harbor more viral DNA and protein than non-T. Importantly, cervical tissue from ART-suppressed HIV women contain high levels of viral DNA and RNA, being the T fraction the principal contributor. These results recognize the lower female genital tract as an HIV sanctuary and identify CD4T as primary targets of HIV infection and viral persistence. Thus, strategies towards an HIV cure will need to consider T phenotypes, which are widely distributed in tissues.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Perea, David|||0000-0003-1562-4740
  • Suppi, Marina|||0000-0002-9042-6659
  • Massana, Núria|||0000-0002-5403-3161
  • Vergara, Ander|||0000-0003-1926-0147
  • Soler, María José|||0000-0003-3621-0766
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Blanco, Julià|||0000-0002-2225-0217
  • García-Pérez, Javier|||0000-0003-0300-1810
  • Alcami, Jose|||0000-0003-0023-7377
  • Serrano-Mollar, Anna|||0000-0002-4990-8162
  • Rosado Rodríguez, Joel|||0000-0001-9308-7827
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Buzón, Maria José|||0000-0003-4427-9413
The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2. The early stages of laboratory identification of therapeutics against pathogens is usually based on the use of immortalized cell lines, as exemplified by many studies screening antivirals against SARS-CoV-2. Cell lines are manipulated for their continuous growth which offers several advantages, however they do not fully reproduce the behavior of primary cells nor the complexity of heterogeneous populations. In this study, we overcome this limitation by using surgical resections to establish human lung tissue (HLT) cell cultures ready for drug evaluation. First, we show that HLT preserves lung cell composition, including the main SARS-CoV-2 cellular target, namely alveolar type-2 cells, as well as the proteins required for viral entry into the cells: ACE2, CD147, TMPRSS2 and AXL. Moreover, using HLT cells we identified new antiviral drug candidates missed by conventional systems, and anti-inflammatory compounds that module molecules associated with SARS-CoV-2 infection. In summary, we have established a physiological model that can be used for the identification of novel anti-SARS-CoV-2 therapeutics and other respiratory pathogens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes

  • Reverté Calvet, Laia|||0000-0003-4690-2387
  • Yeregui, Elena|||0000-0003-2994-4219
  • Olona, Montserrat|||0000-0001-5303-9361
  • Gutiérrez-Valencia, Alicia|||0000-0003-3445-1574
  • Buzón, Maria José|||0000-0003-4427-9413
  • Martí, Anna
  • Gómez-Bertomeu, Frederic
  • Auguet, Teresa
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Benavent-Bofill, Clara
  • Boqué, Carme
  • García-Pardo, Graciano|||0000-0003-0274-6001
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
  • Mestre, Maria Teresa
  • Vidal, Francesc|||0000-0002-6692-6186
  • Viladés, Consuelo|||0000-0002-2991-9593
  • Peraire, Joaquim|||0000-0001-7808-5479
  • Rull, Anna|||0000-0002-8907-7754
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Zinc pyrithione is a potent inhibitor of PL Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

  • Kladnik, Jerneja
  • Dolinar, Ana
  • Kljun, Jakob
  • Perea, David|||0000-0003-1562-4740
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Novinec, Marko
  • Buzón, Maria José|||0000-0003-4427-9413
  • Turel, Iztok
Zinc pyrithione (1a), together with its analogues 1b - h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc pyrithione revealed potent in vitro inhibition of cathepsin L (IC=1.88 ± 0.49 µM) and PL Pro (IC=0.50 ± 0.07 µM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc complexes 1b - h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

  • Kladnik, Jerneja
  • Dolinar, Ana
  • Kljun, Jakob
  • Grau Exposito, Judit
  • Genesca Ferrer, Meritxell
  • Novinec, Marko
  • Buzón Gómez, María José
  • Turel, Iztok
  • Perea Pérez, David
SARS-CoV-2; Inhibition; Zinc, SARS-CoV-2; Inhibició; Zinc, SARS-CoV-2; Inhibición; Zinc, Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc pyrithione revealed potent in vitro inhibition of cathepsin L (IC50=1.88 ± 0.49 µM) and PLPro (IC50=0.50 ± 0.07 µM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc complexes 1b–h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2., The authors acknowledge the financial support from the Slovenian Research Agency ARRS [Research Core Funding No. P1-0175 together with an increase in research programme funding related to the COVID-19 pandemic], and the grant from the Health Department of the Government of Catalonia [DGRIS 1_5] and the Fundació La Marató TV3 [Grants 202104FMTV3 and 202112FMTV3] to M.G. and MJ.B. MJ.B is supported by the Miguel Servet Program funded by the Spanish Health Institute Carlos III [CP17/00179].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV

  • Sanchez-Cerrillo, Ildefonso
  • Martin-Cofreces, Noa B
  • Martínez-Fleta, Pedro
  • de la Fuente, Hortensia
  • Buzón Gómez, María José
  • Calvet-Mirabent, Marta
  • Tsukalov, Ilya
HIV; Immunotherapy; Metabolism, VIH; Inmunoterapia; Metabolismo, VIH; Immunoteràpia; Metabolisme, Background Dysfunction of CD8+ T cells in people living with HIV-1 (PLWH) receiving anti-retroviral therapy (ART) has restricted the efficacy of dendritic cell (DC)-based immunotherapies against HIV-1. Heterogeneous immune exhaustion and metabolic states of CD8+ T cells might differentially associate with dysfunction. However, specific parameters associated to functional restoration of CD8+ T cells after DC treatment have not been investigated. Methods We studied association of restoration of functional HIV-1-specific CD8+ T cell responses after stimulation with Gag-adjuvant-primed DC with ART duration, exhaustion, metabolic and memory cell subsets profiles. Findings HIV-1-specific CD8+ T cell responses from a larger proportion of PLWH on long-term ART (more than 10 years; LT-ARTp) improved polyfunctionality and capacity to eliminate autologous p24+ infected CD4+ T cells in vitro. In contrast, functional improvement of CD8+ T cells from PLWH on short-term ART (less than a decade; ST-ARTp) after DC treatment was limited. This was associated with lower frequencies of central memory CD8+ T cells, increased co-expression of PD1 and TIGIT and reduced mitochondrial respiration and glycolysis induction upon TCR activation. In contrast, CD8+ T cells from LT-ARTp showed increased frequencies of TIM3+ PD1− cells and preserved induction of glycolysis. Treatment of dysfunctional CD8+ T cells from ST-ARTp with combined anti-PD1 and anti-TIGIT antibodies plus a glycolysis promoting drug restored their ability to eliminate infected CD4+ T cells. Interpretation Together, our study identifies specific immunometabolic parameters for different PLWH subgroups potentially useful for future personalized DC-based HIV-1 vaccines., EMG was supported by the NIH R21 program (R21AI140930), the Ramón y Cajal Program (RYC2018-024374-I), the MINECO/FEDER RETOS program (RTI2018-097485-A-I00), by Comunidad de Madrid Talento Program (2017-T1/BMD-5396) and by Gilead becas de investigación (GLD19/00168). EMG and IDS are supported by Centro de Investigación Biomédica en Red (CIBERINF) de Enfermedades Infecciosas (CB21/13/00107). MCM was supported by NIH R21 program (R21AI140930), “La Caixa Banking Foundation (H20-00218) and Gilead becas de investigación (GLD19/00168). MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179), the MINECO/FEDER RETOS program (RTI2018-101082-B-100), and Fundació La Marató TV3 (201805-10FMTV3). EMG and MJB are both funded by “La Caixa Banking Foundation (H20-00218) and by REDINCOV grant from Fundació La Marató TV3. FSM was supported by SAF2017-82886-R and PDI-2020-120412RB-I00 grants from the Ministerio de Ciencia e Innovación, and HR17-00016 grant from “La Caixa Banking Foundation. HF was funded by PI21/01583 grant from Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III. MJC was supported by PID2019-104406RB-I00 from Ministerio de Ciencia e Innovación. ISC was funded by the CM21/00157 Rio-Hortega grant. IT was supported by grant for the promotion of research studies master-UAM 2021.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency

  • Gallego-Cortés, Ana
  • Sánchez Gaona, PhD, Nerea
  • Ruiz Isant, Oriol
  • Pumarola, Felix
  • Ortiz Laredo, Nuria
  • Llano Espinosa, Ines
  • Mañalich-Barrachina, Laura
  • Mancebo Pérez, Cristina
  • Benítez Martínez, Aleix
  • Landolfi, Stefania
  • Castellvi, Josep
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV; Tissue models; Cellular reservoirs, VIH; Modelos de tejido; Reservorios celulares, VIH; Models de teixit; Reservoris cel·lulars, HIV persists in diverse tissues, with distinct cellular reservoirs presenting a major barrier to a cure and requiring targeted therapeutic strategies to address this heterogeneity. Here, we develop tissue models of HIV latency using human tonsillar, intestinal and cervicovaginal tissues. These models reveal differential HIV infection across CD4+ T-cell subpopulations, with ART partially restoring CD4+ T cells and reducing intact HIV DNA. T follicular helper cells (TFH CD69+ CCR7-) are the primary inducible reservoir in tonsils, while tissue-resident memory cells (TRM CD69+ CD49a+) dominate in the intestine. Identification of markers for inducible reservoirs shows that CD69, CD45RO, and PD-1 are shared across tissues, while CXCR5 in tonsils and CD49a in the intestine act as tissue-specific markers. Furthermore, using different latency reversal agents (LRAs) demonstrates that Histone Deacetylase Inhibitors (HDACis) fail to induce HIV in any tissue, the SMAC mimetic AZD5582 is effective only in a resident-memory CD4+ T-cell subpopulation in the intestine, and IL-15 exhibits the broadest reactivation potential across tissues and CD4+ T-cell subsets. These models provide insights into the inducible reservoir's composition in different tissues and inform strategies for its elimination., This study was funded by “la Caixa” Foundation (ID 100010434) under the project code LCF/PR/HR20/00218. This study also received funding from the Agencia Estatal de Investigación project PID2021-123321OB-I00 and PID2024-155881OB-100 supported by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD21-00049, GLD22/00152 and GLD24/00014. MJB is supported by the Miguel Servet programme of the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005), and AGC is a recipient of a PhD fellowship from “la Caixa” Foundation (LCF/BQ/DI20/11780014). The funders had no role in the design of the study, data collection or analysis, decision to publish, or manuscript preparation. We acknowledge María Lázaro and Ruth Peña (JGP research group) for their technical assistance in the production of the HIVBAL viral stock.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà Ferrer, Meritxell
  • Grau Exposito, Judith
  • Buzon, Maria Jose
HIV infections; Restriction factors, Infecciones por VIH; Factores de restricción, Infeccions pel VIH; Factors de restricció, Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption

  • Perea Pérez, David
  • Martin-Gayo, Enrique
  • Zamora Carrillo, Jorge Ivan
  • Sánchez Gaona, Nerea
  • Curran, Adrian
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
NK cell; Bispecific antibody therapy; HIV, Cèl·lules NK; Teràpia d'anticossos biespecífics; VIH, Células NK; Terapia d'anticuerpos biespecíficos; VIH:es, HIV infection remains incurable as the virus persists within a latent reservoir of CD4+T cells. Novel approaches to enhance immune responses against HIV are essential for effective control and potential cure of the infection. In this study, we designed a novel tetravalent bispecific antibody (Bi-Ab32/16) to simultaneously target the gp120 viral protein on infected cells, and the CD16a receptor on NK cells. In vitro, Bi-Ab32/16 triggered a potent, specific, and polyfunctional NK-dependent response against HIV-infected cells. Moreover, addition of the Bi-Ab32/16 significantly reduced the latent HIV reservoir after viral reactivation and mediated the clearance of cells harboring intact proviruses in samples from people with HIV (PWH). However, the in vivo preclinical evaluation of Bi-Ab32/16 in humanized mice expressing IL-15 (NSG-Hu-IL-15) revealed a significant decline of NK cells associated with poor virological control after ART interruption. Our study underscores the need to carefully evaluating strategies for sustained NK cell stimulation during ART withdrawal., This study was supported by the Spanish Secretariat of Science and Innovation, FEDER funds (RTI2018-101082-B-I00, PID2021-123321OB-I00, PDC2022.133836-100), two Gilead fellowships (GLD21/00049, GLD22/00152) as well as partially funded by the PI20/00160 grant from the Spanish Health Institute Carlos III, co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, the CNS2022-135549 grant, funded by MCIN/AEI/10.13039/501100011033 and by the European Union «Next Generation EU»/PRTR. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005). N.S-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (PRE2019-087393). We would like to thank Dr. Julia G. Prado from IrsiCaixa Institute for AIDS Research for generating the viral stock R5-BaL and Jorge Díaz from the Comparative Medicine and Bioimage Centre of Catalonia (CMCIB) for its excellent technical assistance with in vivo animal studies. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response

  • Grau Exposito, Judit
  • Navarro Mercadé, Jordi
  • Curran Fàbregas, Adria
  • Planas Ribas, Bibiana
  • Suanzes Diez, Paula
  • Falcó Ferrer, Vicenç
  • Genesca Ferrer, Meritxell
  • Buzón Gómez, María José
  • Astorga Gamaza, Antonio
  • Burgos Cibrian, Joaquin
HIV; Infectious disease; Reservoir, VIH; Malalties infeccioses; Reservori, VIH; Enfermedades infecciosas; Reservorio, Human immunodeficiency virus (HIV) establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy (ART), but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32., This study was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI17/01470), GeSIDA and the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-10FMTV3) and the Gilead fellowships GLD19/00084 and GLD18/00008. M.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016–076382). The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence

  • Buzón Gómez, María José
  • Astorga Gamaza, Antonio
Marcadors cel·lulars; Virus de la immunodeficiència humana; Persistència viral, Marcadores celulares; Virus de la inmunodeficiencia humana; Persistencia viral, Cell markers; Human immunodeficiency virus; Viral persistence, Purpose of review To discuss the role of CD4+ T cells with active Human immunodeficiency virus (HIV), meaning infected cells with transcriptional and/or translational viral activity during antiretroviral therapy (ART), focusing on new technologies for its detection, potential cell markers for its characterization, and evidences on the contribution of the active HIV reservoir to long-term viral persistence. Recent findings HIV-infected cells expressing viral ribonucleic acid are systematically detected in subjects on long-term ART. In recent years, powerful new tools have provided significant insights into the nature, quantification, and identification of cells with active HIV, including the identification of new cell markers, and the presence of viral activity in specific cell populations located in different cellular and anatomical compartments. Moreover, studies on viral sequence integrity have identified cell clones with intact viral genomes and active viral transcription that could potentially persist for years. Together, new investigations support the notion that the active reservoir could represent a relevant fraction of long-term infected cells, and therefore, the study of its cell sources and mechanisms of maintenance could represent a significant advance in our understanding of viral persistence and the development of new curative strategies. Summary The presence of HIV-infected cells with viral expression during ART has been traditionally overlooked for years. Based on recent investigations, this active viral reservoir could play an important role in HIV persistence., This work was supported by the Spanish Secretariat of Science and Innovation and FEDER funds (grants SAF2015-67334-R and RTI2018-101082-B-I00 [MINECO/FEDER]), and the Fundació La Marató TV3 (grant 201805-10FMTV3). M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). A.A.-G. is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016-076382). The funders had no role in the decision to publish or the preparation of the manuscript.